NDT Pharmaceuticals

NDTP

Biotechnology · Healthcare

Price

$0.51

+0.00 (+0.00%)

Market Cap

$82.1M

Exchange

Other OTC

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+48570.6% over 9y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 302K (2016) → 147.2M (2025)

Winston Score History

The full picture

NDT Pharmaceuticals Inc. is a small biotechnology company focused on developing drugs to treat neurological and psychiatric conditions. It works on experimental medicines that target the central nervous system, meaning the brain and spinal cord. The company is in the research and development stage, meaning it does not yet sell approved products to patients.

NDT Pharmaceuticals makes almost no revenue right now and spends heavily on clinical trials and research, which explains its deeply negative margins. It operates primarily in the United States and, with a market cap of around $100 million, is considered a micro-cap biotech. Companies like this live or die based on clinical trial results — if a drug candidate fails in testing, the company can lose most of its value quickly, and that is the central risk investors face here.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

YoY Growth Rate

EPS data limited

R&D Spend

$0/ year

Research and development spending

Insider Activity

64.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

$80,852 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

NDT Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-233.3%

Thin — -233.3% gross margin

Profit after running costs

Operating Margin

-459.1%

Losing money on operations — -459.1%

Return on the money invested

ROCE

-2.6%

Weak — -2.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-171.9%

Burning cash (-171.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.02

Conservative — low debt load (0.02)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial